ATE225346T1 - Fkbp inhibitoren - Google Patents

Fkbp inhibitoren

Info

Publication number
ATE225346T1
ATE225346T1 AT99926683T AT99926683T ATE225346T1 AT E225346 T1 ATE225346 T1 AT E225346T1 AT 99926683 T AT99926683 T AT 99926683T AT 99926683 T AT99926683 T AT 99926683T AT E225346 T1 ATE225346 T1 AT E225346T1
Authority
AT
Austria
Prior art keywords
fkbp inhibitors
fkbp
inhibitors
Prior art date
Application number
AT99926683T
Other languages
English (en)
Inventor
Martin James Wythes
Michael John Palmer
Mark Ian Kemp
Malcolm Christian Mackenny
Robert John Maguire
James Francis Blake Jr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE225346T1 publication Critical patent/ATE225346T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
AT99926683T 1998-07-20 1999-07-01 Fkbp inhibitoren ATE225346T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815696.1A GB9815696D0 (en) 1998-07-20 1998-07-20 Heterocyclics
PCT/IB1999/001227 WO2000005231A1 (en) 1998-07-20 1999-07-01 Fkbp inhibitors

Publications (1)

Publication Number Publication Date
ATE225346T1 true ATE225346T1 (de) 2002-10-15

Family

ID=10835773

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926683T ATE225346T1 (de) 1998-07-20 1999-07-01 Fkbp inhibitoren

Country Status (45)

Country Link
US (2) US6166011A (de)
EP (1) EP1098894B1 (de)
JP (1) JP3545341B2 (de)
KR (1) KR20010083130A (de)
CN (1) CN1315951A (de)
AP (1) AP2001002045A0 (de)
AR (1) AR016501A1 (de)
AT (1) ATE225346T1 (de)
AU (1) AU756769B2 (de)
BG (1) BG105249A (de)
BR (1) BR9912307A (de)
CA (1) CA2338276C (de)
CO (1) CO5080761A1 (de)
CZ (1) CZ2001224A3 (de)
DE (1) DE69903319T2 (de)
DK (1) DK1098894T3 (de)
DZ (1) DZ2848A1 (de)
EA (1) EA200100051A1 (de)
EE (1) EE200100043A (de)
ES (1) ES2183567T3 (de)
GB (1) GB9815696D0 (de)
GT (1) GT199900113A (de)
HK (1) HK1040706A1 (de)
HN (1) HN1999000101A (de)
HR (1) HRP20010053A2 (de)
HU (1) HUP0103020A3 (de)
ID (1) ID27022A (de)
IL (1) IL140243A0 (de)
IS (1) IS5799A (de)
MA (1) MA26661A1 (de)
NO (1) NO20010299L (de)
NZ (1) NZ508839A (de)
OA (1) OA11586A (de)
PA (1) PA8477601A1 (de)
PE (1) PE20000867A1 (de)
PL (1) PL345705A1 (de)
PT (1) PT1098894E (de)
SI (1) SI1098894T1 (de)
SK (1) SK702001A3 (de)
TN (1) TNSN99146A1 (de)
TR (1) TR200100133T2 (de)
UA (1) UA60368C2 (de)
WO (1) WO2000005231A1 (de)
YU (1) YU83100A (de)
ZA (1) ZA200100229B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
GB0008939D0 (en) * 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
IL155952A0 (en) 2000-11-28 2003-12-23 Wyeth Corp Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7186518B2 (en) * 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
US8354557B2 (en) 2008-06-17 2013-01-15 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
TWI534142B (zh) 2011-03-15 2016-05-21 大正製藥股份有限公司 Azole derivatives
EP2705856A1 (de) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Verbindungen zur Behandlung von neurodegenerativen Erkrankungen
CN106138044B (zh) * 2016-07-15 2017-05-03 鲁俊东 一种治疗腰椎间盘突出症的药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
FR2696176B1 (fr) * 1992-09-28 1994-11-10 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
GB9700597D0 (en) * 1997-01-14 1997-03-05 Sandoz Pharma Uk Organic compounds
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
US6686357B1 (en) * 1999-07-15 2004-02-03 Pfizer, Inc. FKBP inhibitors
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
WO2000005231A1 (en) 2000-02-03
NO20010299L (no) 2001-03-15
GB9815696D0 (en) 1998-09-16
SI1098894T1 (en) 2002-12-31
AU756769B2 (en) 2003-01-23
DK1098894T3 (da) 2002-10-28
NO20010299D0 (no) 2001-01-18
BR9912307A (pt) 2001-05-02
CA2338276C (en) 2007-01-09
US6166011A (en) 2000-12-26
PE20000867A1 (es) 2000-08-31
CO5080761A1 (es) 2001-09-25
AR016501A1 (es) 2001-07-04
SK702001A3 (en) 2001-12-03
IL140243A0 (en) 2002-02-10
EP1098894B1 (de) 2002-10-02
MA26661A1 (fr) 2004-12-20
ES2183567T3 (es) 2003-03-16
HUP0103020A3 (en) 2002-10-28
CZ2001224A3 (cs) 2001-08-15
YU83100A (sh) 2003-04-30
ID27022A (id) 2001-02-22
EA200100051A1 (ru) 2001-08-27
GT199900113A (es) 2001-01-09
CA2338276A1 (en) 2000-02-03
EP1098894A1 (de) 2001-05-16
US20040058905A1 (en) 2004-03-25
EE200100043A (et) 2002-06-17
PA8477601A1 (es) 2000-09-29
DE69903319T2 (de) 2003-01-30
AU4385599A (en) 2000-02-14
KR20010083130A (ko) 2001-08-31
ZA200100229B (en) 2002-04-09
HUP0103020A2 (hu) 2002-05-29
UA60368C2 (uk) 2003-10-15
TR200100133T2 (tr) 2001-06-21
BG105249A (en) 2001-11-30
AP2001002045A0 (en) 2001-03-31
TNSN99146A1 (fr) 2005-11-10
CN1315951A (zh) 2001-10-03
IS5799A (is) 2000-12-29
HK1040706A1 (zh) 2002-06-21
JP2002521381A (ja) 2002-07-16
HRP20010053A2 (en) 2001-12-31
OA11586A (en) 2004-07-26
PL345705A1 (en) 2002-01-02
HN1999000101A (es) 2000-11-11
DZ2848A1 (fr) 2003-12-01
DE69903319D1 (de) 2002-11-07
JP3545341B2 (ja) 2004-07-21
PT1098894E (pt) 2003-02-28
NZ508839A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
ATE310722T1 (de) Nicht-immunsuppressive fkbp rotamase inhibitoren
PT1181017E (pt) Inibidores de metaloproteases
PT1114051E (pt) Inibidores de p38
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
DE69716615D1 (de) Heterozyklische metalloproteaseinhibitoren
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
NO20004550D0 (no) Enzyminhibitorer
ATE231132T1 (de) Heterocyclische metalloprotease inhibitoren
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
NO20012980D0 (no) Proteaseinhibitorer
DE69939689D1 (de) Caspase inhibitoren
PT1194404E (pt) Inibidores de aspartil-protease
DE59806475D1 (de) Urokinase-inhibitoren
NO20003814L (no) Trombininhibitorer
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO20010660D0 (no) Isolator
ATE225346T1 (de) Fkbp inhibitoren
MA24877A1 (fr) INHIBITEURS DE PROTéASES
NO993161L (no) Cyklooksygenaseinhibitor
DE69930852D1 (de) Prenyltransferase-inhibitoren
SE9802118D0 (sv) Mycobacterial inhibitors
DK2277920T3 (da) Komplementaktiveringsinhibitorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee